JAK1 and urticaria: An understanding of the effect of IgE sensitization or type 2 inflammation on the pathogenesis of urticaria, such as in MCs and basophils, may allow for the discovery of therapies (such as omalizumab, allergen-specific immunotherapy, dupilumab, and Jak1 inhibitors) that target IgE sensitization and type 2 inflammatory factors in the setting of CU.